signals for the SHF include a Wnt2 pathway required for pSHF expansion 18 and a retinoic acid-mediated mechanism that restricts AHF growth. 19 Recently, it was shown that 3′ Hox a1 and b1 genes are regulated by retinoic acid and that these transcription factors act as effectors of SHF patterning. 20 Previously, using the Mlc1v-lacZ-24 transgenic reporter of Fgf10, we provided some evidence for an atrial fate of the Islet1+/Fgf10− pSHF cell population. 21 In this study, we have analyzed in detail the fate of small groups of pSHF cells using lipophilic dye labeling and mouse embryo culture to form a fate map of the Islet1+/Fgf10− subdomain. This shows that pSHF is a source of cells for both inflow and outflow cardiac regions, with left-right, craniocaudal, and stage-dependent patterns of contribution.
Methods
Outbred MF1 mice were used, except for the clonal analyses. The pSHF was defined by in situ hybridization for Islet1 and Mlc2a expression 10 and by X-gal staining of the Fgf10 transgenic reporter line, 8 Mlc1v-nLacZ- 24 . Cells within the Mlc2a−/Islet1+/Fgf10− pSHF region (4-and 6-somite stages; Online Figures IH and II) or the most caudal Mlc2a−/Islet1+/Fgf10+ region (2 somites; Online Figure IG ) were labeled by injection of a lipophilic carbocyanine, DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate), DiO (3,3'-dioctadecyloxacarbocyanine perchlorate) or DiR (1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide), as described previously. 22 Initial studies showed that injections label a contiguous group of 20 to 30 cells within the splanchnic mesoderm layer (see Online Data Supplement, Online Figure IVA-IVC).
Injected embryos were photographed immediately (t 0 ), and the exact localization of dye was systematically recorded using a grid overlay (Online Figure VA-VD) . Embryos were cultured for 40 hours (t 40 ) in rolling bottles and then hearts were isolated, fixed, and dye distribution examined by confocal microscopy. The locations of label were charted onto systematically defined cardiac regions (Online Figure VE -VH), each of which is identified here by a color/symbol code (Online Figure VI) when related back to the site of injection.
Clonal analyses were made at E8.5 in embryos from the α-cardiac actin nlaacZ1�1/+ transgenic line that spontaneously generates random clones of β-galactosidase (β-gal)-positive myocardial cells, as previously described. 12, 13 Statistical methods are given in the Online Data Supplement.
Results

Establishing the Extent of pSHF With Molecular Markers
By definition, we consider the pSHF as that part of the Islet1expressing SHF that does not express AHF markers, such as Fgf10. 21 We charted this domain precisely in embryos of 2 to 6 somites, using Islet1, Fgf10 (Mlc1v-nLacZ-24), and Mlc2a (myocardial marker for crescent) expression (Online Figures  IB, IC, IE, IF, IH, and II) . At 2 somites, even the most caudal region of the Islet1-expressing domain also showed Mlc1v-nLacZ-24 staining (Online Figure IA , ID, and IG), so no clear pSHF can be defined at this stage using these techniques.
pSHF Cells Contribute to the Venous Pole of the Heart With Craniocaudal, Left-Right, and Stage-Dependent Patterns
Previously, we showed that pSHF contributes to the ipsilateral atrium. 21 Here, we find that the left pSHF at 4 to 6 somites contributes to the dorsal wall of the left (common) atrium (LA), whereas the right pSHF contributes to both the dorsal and ventral regions of the right (common) atrium (RA; Figure 1A -1D). Interestingly, the right pSHF also contributes contralaterally to the ventral side of the LA ( Figure 1C-1G ). Observation of labeled cells in the ventral LA after left pSHF injection was rare (2 cases, ≈2% injections; Figure 1C -1G for details).
Considering the whole pSHF, about two thirds of all injections resulted in labeling of the atrium, and this proportion did not differ between the 4-and 6-somite stages (65% and 63% of injections, respectively; Online Figure IIA ). However, the cranial and caudal halves of the pSHF show clear spatial differences in contribution, again similarly at 4 and 6 somites. The caudal portion of the pSHF was less likely than the cranial to contribute to the atria ( Figure 1C and 1D; Online Figure IIIC and IIID). Furthermore, the caudal portion also contributes more distally to the atria and to the sinuatrial region ( Figure 2A and 2B and Figure 3C and 3D), whereas more cranial injections yielded labeled cells in proximal portions of the atria, closer to the atrioventricular junction.
There seems to be a difference in the allocation process between the dorsal and ventral RA. Of all injections that labeled the RA, 46% contributed to the dorsal portion only, 51% to dorsal and ventral, and 3% to ventral only. So, 97% of the ventral label also displayed dorsal label, which could be accounted for by cells contributing first dorsally, then a subpopulation moving ventrally. In support of this, contiguous regions of labeled cells were observed in the lateral dorsal region through the right lateral wall and into the ventral portion ( Figure 2A-2C) .
The right cells that contribute contralaterally to the ventral LA lie in the cranial region of the pSHF: 10% cranial injections compared with 2% caudal. Furthermore, the vast majority (81%) of injections that resulted in contralateral contribution also resulted in ipsilateral labeling in the ventral and dorsal side RA. Again, this may reflect a progressive contribution from the cranial right pSHF to dorsal right, ventral right, and then ventral left regions of the atrium.
Injections in the pSHF also produced labeled cells in the sinus venosus region, which we define at this stage as that region caudal to the visible sulcus at the atrium-body wall junction ( Figures 1A, 1B , 2A, 2B, 2D, and 2E). Of all cases of sinus venosus contribution, 70% showed contribution to the atrium also, with a contiguous region of labeled cells. However, in contrast to the observations in the atria, contralateral labeling from one side of the pSHF to the other sinus venosus was very rare (1 and 2 cases from left and right [L&R], respectively). The overall area occupied by sinus venosus precursors in the pSHF is somewhat greater than that for the atria, extending more caudally and medially ( Figure 2D and 2E and Online Figure IIIC and IIID). In accordance with observations in the atria, sinus venous-destined cells were more likely to reside in the caudal half of the pSHF at the 4-somite stage ( Figure 2D and 2E and Online Figure IIC ). However, contrary to the atria, there was a clear stage difference between the 4-and 6-somite stages, with consistently more sinus venosus contribution at the older stage (Online Figure IIC ). This indicates that sinus venosus precursors are added to the domain of Isl1 expression between the 4-and 6-somite stages. We did not systematically analyze contribution to the endocardium (indeed all observations described here refer to myocardium), but sectioning of hearts shows that, in the inflow region, labeled cells are found in both endocardium and myocardium ( Figure 2F and 2G). This is consistent with analyses of Islet1-cre mice, suggesting a common origin from Islet1expressing precursors for these 2 cell types. 10
Left and Right pSHFs Contribute Differently to the AVC Region
Overall, 14% of pSHF injections at 4-and 6-somite stages showed labeled cells in the atrioventricular canal (AVC) region, of which the vast majority (97%) also showed atrial contribution. Strikingly, the contributions to the AVC from the left and right pSHFs were markedly different. Consistently, labeled cells from the right pSHF contributed to the inferior AVC ( Figure 3A , 3B, and 3E-3G), whereas cells from the left pSHF contributed to the superior and left lateral AVC (hereafter superior AVC), corresponding with the outer curvature of the AVC (Figure 3C , 3D, and 3E-3G). Curiously, no labeled cells from the pSHF were observed in the right lateral side of the AVC, corresponding with the inner curve, closer to the OFT region. Furthermore, there were no cases of an individual injection resulting in labeling of both the inferior and the superior AVC. Figure IID) . In contrast to the sinus venosus, the proportion of injections that resulted in AVC-labeled cells decreased between 4 and 6 somites (Online Figure IIA) . This indicates that AVC precursor cells have left the SHF by the 6-somite stage and have been fully recruited to the heart tube.
There is a close relationship between contributions to regions of the atria and regions of the AVC. Thus, in 100% of cases showing labeled cells in the superior AVC region, there were also labeled cells in the dorsal LA. Conversely, 88% of inferior AVC-labeled hearts also showed contribution to the ventral LA. There were no examples of superior AVC plus ventral LA nor of inferior AVC plus dorsal LA patterns of labeling in this study. L&R pSHF contributions to atria and AVC are summarized in Figure 7B and 7C.
We aimed to gain insight into the clonal relationships between the inferior and superior AVC, as well as between the AVC and inflow regions. To investigate these relationships by a complementary approach, we studied α-cardiac actinn-laacZ1.1/+ E8.5 embryos, which allows retrospective clonal analysis of myocardial cells in the mouse heart. 12 Thus, from a collection of 4967 α-cardiac actinnlaacZ1.1/+ embryos of 8 to 21 somites, we selected all those that had β-gal-positive groups of cells in the AVC or atria (Online Table I ). Among these 96 embryos, 33% showed β-gal-positive cells in the superior AVC ( Figure 4C , 4F, and 4H), whereas only 10% displayed positive cells in the inferior AVC ( Figure 4E , 4G, and 4I). This difference, in a random collection of clones, probably reflects the difference in size, and therefore numbers of progenitor cells, between these 2 regions, the superior AVC being larger. The exclusive participation in either region of the AVC in most embryos suggests that these 2 regions have different clonal origins and that up to the stage of 21 somites there is no intermixing of these populations. We observed only 2 embryos ( Figure 4A and 4B), with β-gal expressing cells that occupied both the inferior and the superior AVC. Statistical analysis (Online Table I ) suggests that these clones arise from common precursors of the 2 AVC regions. Indeed, the clone in Figure 4A , which contains 1370 β-gal-positive cells colonizing all regions of the heart, is the biggest clone of the collection, indicative of a very early event of recombination. The other clone colonizing both AVC regions ( Figure 4B ) contains 42 β-gal-positive cells in the right and left ventricles and the AVC. It has been classified as a large clone of the first myocardial lineage. 13 However, most large clones of the first (n=13) or second (n=13) myocardial lineage, as well as very large clones arising from common precursors of the first and second myocardial lineages (n=4; Figure 4C and 4E), have an exclusive contribution to either the superolateral or the inferior AVC. This means that the segregation between the 2 AVC regions precedes the segregation of the 2 lineages ( Figure 4D) .
β-gal-positive labeling restricted to a region of the AVC was frequently associated with positive cells in the atria (80%). The majority (63%) of embryonic hearts with LacZ-labeled cells in the superior AVC only also showed β-gal-positive cells in the dorsal LA ( Figure 4H ), and less frequently (20%) in the ventral LA ( Figure 4C ). There was a single example of LacZ labeling on both the superior AVC and right atrium. Statistical analysis confirms the clonal relationship between the superior AVC and the LA, but not with the RA. In contrast, all hearts that showed β-gal-positive cells in the inferior-only AVC also contained LacZ-labeled cells in the ventral LA or the RA or both (Figure 4E, 4G, and 4I ). Statistical analysis indicates that the inferior AVC is clonally related to the ventral LA and the RA, but not to the dorsal LA (Online Table II ).
Taken together, these results suggest that the inferior and superior regions of the AVC have different origins, and the inferior part is clonally related to the ventral portion of the atria, whereas the superior portion is clonally related to the LA ( Figure 4D ). This is wholly consistent with our dye labeling data, and given our conclusion that left pSHF contributes to the dorsal wall of the LA, we conclude that the bulk of AVC (the superolateral portion) is also of left pSHF origin.
pSHF Cells Colonize the Arterial Pole of the Heart
Interestingly, labeling of the most cranial portions of the pSHF in embryos from 4 to 6 somites resulted in labeled cells at the arterial pole of the developing heart ( Figure 5 ). At the 25-somite stage examined, our data show an ipsilateral cell contribution from the pSHF to the OFT (summarized in Figure 7D ). We found OFT precursor cells in an extensive area of the pSHF, overlapping with those obtained for the inflow tract (IFT)/AVC cardiac regions ( Figure 5H -5J and Online Figure IIIG and IIIH). Almost all OFT-labeled embryos also presented staining of the IFT (94%), suggesting that IFT-and OFT-derived cells may share a common precursor pool in the pSHF and the pSHF may be composed of an intermingling of IFT-destined plus OFT-destined cells.
As previously described for IFT and AVC-destined cells, OFT precursor cells followed a craniocaudal pattern of contribution, that is, the OFT contribution was higher in the cranial portions of the pSHF ( Figure 5H 
pSHF Supplies Fgf10-Expressing and Nonexpressing Cells to the OFT
Previous studies, including those using the Mlc1v-nLacZ-24 reporter, have demonstrated that much of the OFT is derived from Fgf10-expressing cells. 8 Our results, showing a contribution of the Fgf10-negative pSHF to the OFT, led us to ask whether or not these cells switch on Fgf10 when contributing to the arterial pole. Sections of OFT from Mlc1v-nLacZ-24 embryos show a mix of β-gal-positive and β-gal-negative cells ( Figure 6A-6D) . We dye-injected the pSHF of Mlc1v-nLacZ-24 embryos producing dye labeling of the dorsal pericardial wall at t 40 , overlapping with the β-gal domain of Mlc1v-nLacZ-24 staining ( Figure 6E-6F ). Isolation of this region and further examination demonstrated that the dye was localized in β-gal-negative and β-gal-positive cells ( Figure 6G-6I ). However, we cannot estimate what fraction of all OFT contributing pSHF cells do not express Fgf10. Also, we cannot rule out the possibility that there is slow or incomplete activation of the Mlc1v-nLacZ-24 transgene in this population.
The Posterior-Most SHF at 2 Somites Is Predominantly of OFT Fate
We find that the posterior-most portion of Islet1+ splanchnic mesoderm at 2 somites also expresses Fgf10, showing that there is no pSHF, by our molecular definition, at this stage. Nevertheless, we labeled the posterior-most Islet1+ region of 2 somite embryos and found that 95% contributed to the OFT with only 48% showing IFT labeling (n=10; Online Figure  IIF ). This contrasts with the pSHF at 4 and 6 somites, which is mainly destined to form the inflow region. At 2 somites, inflow progenitors lie slightly more medial than outflow progenitors ( Figure 7A) . The contribution to the inflow cardiac regions displayed, overall, similar left-right and craniocaudal patterns to those observed at 4 to 6 somites (data not shown). These observations suggest that from the 2-somite stage there is recruitment of cells to the pSHF, with progressive anteriorward movement of cells within the SHF.
Discussion
Craniocaudal Patterning of the pSHF
Several lines of evidence have shown that the fate of cells from the SHF in the mouse varies according to the anteroposterior (craniocaudal) position within this region. An anterior domain is marked by the expression of genes, including Fgf8, Fgf10, Tbx1, and an Mef2c enhancer, and forms the OFT and right ventricle. 8, 10, 15, 16 A posterior domain contributes to the atrial chambers. 10, 21 We now show that there is further craniocaudal patterning within the pSHF domain, although without sharp boundaries. showing that the left/right regionalization of the heart field, which will give rise to the superior/inferior AVC, respectively, precedes the segregation between the first/second myocardial lineages. Letters in brackets refer to the panels showing an example of such precursor (the color code lilac=of left origin and red=of right origin is also used in Figure 7 and is different from the scheme used in other Figures). LV indicates left ventricle; 10s, 11s, 21s, 10-, 11-, and 21-somite stage, respectively; LA, left atrium; RA, right atrium; AVC, atrioventricular canal; OFT, outflow tract; SAVC, superior atrioventricular canal; VLA, ventral side of the left atrium; IAVC, inferior atrioventricular canal. The most cranial pSHF contributes to the atrioventricular canal, the most caudal part contributes to the sinus venosus, and atrial progenitors lie predominantly in between. This suggests that cells within the pSHF add sequentially to the heart tube, with anteroposterior position predicting regional contribution to the heart, from outflow to inflow. Little is known of the molecular mechanisms that may encode craniocaudal identity within the pSHF. Retinoic acid signaling limits the extent of the SHF, 19 and recently it has been shown to be required for the correct deployment of Hox-expressing SHF cells. 20 Furthermore, regionalized expression of Hoxb1 and Hoxa1 seems to be required for anteroposterior patterning of the SHF. 20 Importantly, at the stages examined here, the cranial pSHF contributes asymmetrically to the left and right sides of the heart, whereas derivatives from the caudal pSHF contribute symmetrically. We have looked at pSHF contributions to the heart at the 20-to 25-somite stage, and the region we have identified as the sinus venosus will develop further into inflow regions of the atria, the coronary sinus, and proximal parts of the caval veins, so it is possible that some asymmetric contributions might be revealed at later stages. However, a companion article 23 to this demonstrates clonal relationships between the LA and the left superior caval vein, and between the RA and the right superior caval vein at E14.5, thus strongly supporting the progressive Figure 7 . A, At 2 somites, outflow precursors are located more medially in second heart field (SHF) than inflow progenitors, although there is extensive overlapping. B to D, A summary of the contributions to the heart from the right (red) and left (lilac) posterior SHF (pSHF). E, A model of the movement of pSHF cells into the heart during the morphogenetic processes of looping (ventral and dorsal views; hearts artificially stretched out, inflow to outflow; color scheme as in Online Figure V) . Cells from the left pSHF move to populate the left sinus venosus (light brown), dorsal left atrium (light green), and superior/medial atrioventricular canal (light yellow). In contrast, more cranial right pSHF cells move to the ventral (dark blue) right atrium (dark blue), ventral left common atrium (light blue), and inferior portions of the atrioventricular canal (dark yellow). Cells more caudally within the right pSHF contribute to the dorsal right atrium (dark green) and right sinus venosus (dark brown). RV indicates right ventricle; RA, right atrium; LV, left ventricle; 2s, 20s, 4s, 6s, 8s, 10s, 2-, 20-, 4-, 6-, 8-, and 10-somite stage, respectively; OFT, outflow tract; IFT, inflow tract; DLA, dorsal side of the left atrium; SAVC, superior atrioventricular canal; IAVC, inferior atrioventricular canal.
ipsilateral development that we have observed from the pSHF to the future atria and systemic veins.
The sequential craniocaudal arrangement of precursors within the mouse pSHF is stage-dependent and is overlapped by progenitors of the arterial pole (see below). In apparent contrast, in the chick the medial and lateral cardiogenic mesoderm contribute to the most cranial and caudal portions of the heart, respectively. 24 We see no evidence of mediolateral patterning at 4 to 6 somites in the mouse, but this is probably explained by the earlier stage examined in the chick before splanchnic mesoderm rotation. 25 At 2 somites, we do observe a more medial and lateral disposition of outflow and IFT progenitor cells, respectively, comparable with the arrangement in the chick heart-forming regions. 24 
pSHF Also Contributes to the Arterial Pole
We find a robust contribution of the more cranial part of the pSHF to the arterial pole, as well as to the inflow regions. This may seem surprising, given that genetic tracing studies suggested that the OFT is entirely derived from the AHF. 8, 10, 15, 16 However, some previous studies in the chick 26 and recent genetic tracing and clonal studies in the mouse support this notion. Cre tracing shows that pSHF cells that have expressed Hoxb1, Hoxa1, and Hoxa3 contribute not only to the inflow but also to the arterial pole, specifically to the OFT myocardium of the pulmonary trunk. 20 In addition, clonal analysis in the E8.5 heart 13 and E14.5 heart 23 shows a clonal relationship between the atria and the OFT myocardium.
From our current studies, we are not able to relate left and right pSHF progenitors to the pulmonary or aortic parts of the OFT. At the 20-to 25-somite stage at which we assessed contribution, the left pSHF contributed to the left side of the OFT and the right side similarly. However, we and others have shown a functional rotation of the OFT at later stages of development, which moves cells from the left side to populate the subpulmonary myocardium, 27 and there is a clonal relationship between pulmonary myocardium and left head muscles derived from the SHF. 28 As is the case for the inflow, we found evidence for sequential addition of cells from the pSHF to the OFT, with progenitors labeled at 4 somites contributing proximally and at 6 somites distally. A similar sequential relationship is seen in descendants of Hoxb1-expressing cells, which populate the proximal OFT, and Hoxa1 and Hoxa3 descendants that appear more distally. 20 As discussed, there are clonal and genetic data that support the existence of SHF cells that are progenitors of both outflow and inflow myocardium. Because we labeled groups of cells, we cannot draw any conclusions about lineage relationships, but, nevertheless, it is very clear from our observations that adjacent pSHF cells contribute to both poles of the heart, which raises questions about their paths of movement and how they are allocated to one pole or the other. The majority of pSHF cells move into the atrioventricular canal, atria, and sinus venosus, which seems to be a contiguous route to the heart tube via the sinus horns. In contrast, those pSHF cells that contribute to the OFT are likely to move via the dorsal pericardial wall, which is the location of the AHF cells that form the majority of the OFT. This is compatible with the caudal movement of the outflow region of the heart, relative to the pharyngeal region, over this time period, and we have observed labeled cells in the dorsal pericardial wall at 20 somites after labeling of pSHF at 4 to 6 somites. It is possible that this pathway of migration is controlled by Tbx1. It has been shown that, in Tbx1 −/− mice, AHF cells marked by the Mlc1v-nLacZ-24 transgene are found ectopically in the dorsal RA, rather than in their normal location in the OFT. 29 If pSHF cells move to the OFT via the dorsal pericardial wall, which is populated by AHF cells, it may be expected that the originally pSHF cells switch on AHF molecular markers during their relocation. Again using the Mlc1v-nLacZ-24 transgene marker, we found that this is the case for some cells labeled in the pSHF, but apparently not all. It is possible that some cells switch on AHF markers slowly, so are not yet expressing at the 20-to 25-somite stage we assessed, or that the transgene is not fully reflecting endogenous Fgf10 expression or that Fgf10 does not mark all AHF cells. Alternatively, the OFT at this stage may be a molecular mosaic, which has not been previously reported.
Left-Right Asymmetric Contributions From the pSHF
We observed 2 marked left-right asymmetries in pSHF contributions, in relation to the atrioventricular canal and to regions of the atria. The left pSHF gives rise to the myocardium overlying the superior atrioventricular region, whereas the right pSHF contributed to the inferior region. Labeling much earlier, at the 4-cell stage, has shown this same leftsided origin of the superior AVC region in Xenopus 30 but has not been reported previously in mammals. Left-right asymmetries in heart development, excepting looping, are controlled by the left-sided expression of Pitx2c, which is known to pattern the SHF. 21 Pitx2 is strongly expressed in superior, but not inferior, atrioventricular myocardium. 31 Thus, Pitx2 is expressed in cells at the origin and destination of the movement from left pSHF to superior region of the atrioventricular canal, but it is not clear whether Pitx2 is required for this relocation. Pitx2c mutant hearts have AVC abnormalities, 32 but any relationship to movement of cells from the left pSHF is untested.
Although the pSHF predominantly contributes to the ipsilateral atria, as previously reported in mouse 21 and chick, 25 we found that the right pSHF contributes to a subportion of the left ventral atrium. It is not clear what region of the fully formed atrium is represented in the left ventral atrium at the 20-to 25-somite stage, but again there is a correlation with Pitx2 expression. Recent detailed analysis of Pitx2 expression, using a reporter transgene, shows that at E9.5 the ventral LA and inferior AVC are Pitx2-negative, whereas the dorsal region is positive, with a domain extending over the superior AVC. 31 Our clonal analyses show that the 2 lineages which give rise to left and right progenitor populations segregate from common precursors before the separation of the first and second heart lineages ( Figure 4D ). This is compatible with the common precursors being located in the primitive streak and the
